You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • THU0151 Multicenter, Open-Label Study To Evaluate The Predictability of Disease Control at Week 52 Based on Early Response To Certolizumab Pegol (in Combination with Methotrexate) in Italian Patients with Moderate To Severe Rheumatoid Arthritis: The CZP-…

Article info

Article menu
Download PDFPDF
Poster Presentations
Rheumatoid arthritis - anti-TNF therapy
THU0151 Multicenter, Open-Label Study To Evaluate The Predictability of Disease Control at Week 52 Based on Early Response To Certolizumab Pegol (in Combination with Methotrexate) in Italian Patients with Moderate To Severe Rheumatoid Arthritis: The CZP-Speed Study

Authors

Citation

Sarzi-Puttini P, Filippucci E, Adami S, et al
THU0151 Multicenter, Open-Label Study To Evaluate The Predictability of Disease Control at Week 52 Based on Early Response To Certolizumab Pegol (in Combination with Methotrexate) in Italian Patients with Moderate To Severe Rheumatoid Arthritis: The CZP-Speed Study
Annals of the Rheumatic Diseases 2016;75:236-237.

Publication history

  • First published July 15, 2016.
Online issue publication 
July 15, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions